Flexicon FF30 – new and improved tabletop filling and capping machine
23 February 2011 | By Content Communications
Flexicon Liquid Filling, is introducing a new and improved version of its established FF30 tabletop filling and capping machine...
List view / Grid view
23 February 2011 | By Content Communications
Flexicon Liquid Filling, is introducing a new and improved version of its established FF30 tabletop filling and capping machine...
23 February 2011 | By AstraZeneca
The FDA has approved the inclusion of data from two clinical studies...
23 February 2011 | By Packer Forbes Communications
Patients with advanced renal cell carcinoma, can access Votrient® on the NHS...
22 February 2011 | By Gilead Sciences
Gilead Sciences, Inc. & Calistoga Pharmaceuticals, Inc., announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million...
22 February 2011 | By The Scott Partnership
ERT announced the appointment of Eric Ian Schwartz as Executive Vice President and Chief Legal Officer effective February 22...
22 February 2011 | By Peter Huber Kältemaschinenbau GmbH
ATEX solutions for zones 1 & 2, offer two options to address application complexities...
21 February 2011 | By kdm communications limited
New cell lines offer cellular models of cancer that are expected to enhance development of drugs for personalised medicine...
21 February 2011 | By Roche
Role will focus on disorders such as schizophrenia, neurodegeneration, treatment-resistant depression & neurodevelopment...
21 February 2011 | By AstraZeneca
AstraZeneca joins rivals looking to sidestep tougher rules on imported medicines as Russia drives to support domestic industry...
18 February 2011 | By GE Healthcare
Kieran Murphy succeeds retiring Peter Ehrenheicurrent as Life Sciences President and CEO on 31 July 2011...
17 February 2011 | By kdm communications limited
Sigma Life Science, today announced the release of OligoArchitect™...
17 February 2011 | By Novartis
Novartis announced that effective March 2, Naomi Kelman is appointed Head of the Novartis OTC Division...
16 February 2011 | By Roche
The phase III study will investigate a subcutaneous formulation of MabThera for patients with non-Hodgkin’s lymphoma...
16 February 2011 | By Hudson Robotics, Inc.
Hudson is working with distributors and end users across Europe to bring its valued lab solutions to the European market...
15 February 2011 | By The Scott Partnership
Award recognises its role as the world's leading provider of analytical light scattering instrumentation...